04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
22:27 , Nov 6, 2018 |  BioCentury  |  Finance

Advancing AlzeCure

Stockholm-based AlzeCure Pharma AB is planning to raise SEK200 million ($22 million) in an IPO on NASDAQ First North Premier to bring both arms of its Alzheimer’s disease portfolio to the clinic. In a prospectus...
19:04 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) reported detailed efficacy data from the Phase III A4091056 trial evaluating tanezumab compared with placebo to treat osteoarthritis pain. The data showed tanezumab led to...
23:25 , Oct 24, 2018 |  BC Extra  |  Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) reported detailed efficacy data late Tuesday from the Phase III A4091056 trial evaluating tanezumab compared with placebo to treat osteoarthritis pain. The data showed tanezumab...
18:45 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

FDA approves first drug for neurotrophic keratitis

FDA approved Oxervate cenegermin from Dompe Farmaceutici S.p.A. (Milan, Italy) to treat neurotrophic keratitis, a rare eye disease. Oxervate is the first drug approved in the U.S. for the indication, according to the agency. A...
22:06 , Aug 22, 2018 |  BC Extra  |  Company News

FDA approves first drug for neurotrophic keratitis

FDA approved Oxervate cenegermin from Dompe Farmaceutici S.p.A. (Milan, Italy) to treat neurotrophic keratitis, a rare eye disease. Oxervate is the first drug approved in the U.S. for the indication, according to the agency. A...
17:24 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

Regeneron, Teva’s anti-NGF mAb meets 16-week endpoints in Phase III for OA pain

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said fasinumab met the co-primary endpoints at week 16 in a substudy of the larger Phase III FACT LTS & OA trial to...
21:24 , Aug 16, 2018 |  BC Extra  |  Clinical News

Regeneron, Teva’s anti-NGF mAb meets 16-week endpoints in Phase III for OA pain

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said fasinumab met the co-primary endpoints at week 16 in a substudy of the larger Phase III FACT LTS & OA trial to...
16:19 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Pfizer's tanezumab meets in Phase III for OA pain

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) said tanezumab met the three co-primary endpoints compared with placebo in the Phase III A4091056 trial to treat osteoarthritis pain. Pfizer said the data support...
21:41 , Jul 18, 2018 |  BC Extra  |  Clinical News

Pfizer's tanezumab meets in Phase III for OA pain

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) said tanezumab met the three co-primary endpoints compared with placebo in the Phase III A4091056 trial to treat osteoarthritis pain. Pfizer said the data support...